相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study.
Hirva Mamdani et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hironobu Hashimoto et al.
LANCET ONCOLOGY (2020)
Final analysis of single-arm confirmatory study of definitive chemoradiotherapy including salvage treatment in patients with clinical stage II/III esophageal carcinoma: JCOG0909.
Yoshinori Ito et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909
Shuichi Hironaka et al.
ESOPHAGUS (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato et al.
FUTURE ONCOLOGY (2019)
Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).
Ken Kato et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
O-012The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
J Metges et al.
ANNALS OF ONCOLOGY (2019)
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
H. Chung et al.
ANNALS OF ONCOLOGY (2019)
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Yuko Kitagawa et al.
ESOPHAGUS (2019)
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Yuko Kitagawa et al.
ESOPHAGUS (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
Hidekazu Hirano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)
Mitsumi Terada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma
Kazuki Sudo et al.
ONCOLOGY (2018)
Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0
Soichi Odawara et al.
EUROPEAN JOURNAL OF RADIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.
Jaffer A. Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Recent advancements in esophageal cancer treatment in Japan
Yoshihiro Tanaka et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2018)
Immunotherapy for esophageal squamous cell carcinoma : a review
Kosaku Mimura et al.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (2018)
The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma
Peter S. N. van Rossum et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A)
Motoo Nomura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Russell D. Petty et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Karyn A. Goodman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.
Ronan Joseph Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Victor A. Gall et al.
CANCER RESEARCH (2017)
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
J. V. Reynolds et al.
BMC CANCER (2017)
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
Jens Hoeppner et al.
BMC CANCER (2016)
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer
Tomoya Yokota et al.
BRITISH JOURNAL OF CANCER (2016)
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study)
Kozo Kataoka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Sarah Derks et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)
Kenichi Nakamura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
Nobutoshi Ando et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Immunogenic Tumor Cell Death Induced by Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma
Yoshiyuki Suzuki et al.
CANCER RESEARCH (2012)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PHASE II STUDY OF CHEMORADIOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR STAGE II-III ESOPHAGEAL SQUAMOUS CELL CARCINOMA: JCOG TRIAL (JCOG 9906)
Ken Kato et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
18F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial
Christian Meyer Zum Bueschenfelde et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708)
Hoichi Kato et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:: The MUNICON phase II trial
Florian Lordick et al.
LANCET ONCOLOGY (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516)
K Ishida et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
分享论文
